|
|
|
| Curative Efficacy of Milrinone Combined with Dopaminein Treatment of Chronic Heart Failure and Effects on CysC NT-proBNP IL-6 Levels |
| LI Fei, HU Jun, FENG Qifan |
| Xuancheng People's Hospital, Anhui Xuancheng 242000, China |
|
|
|
|
Abstract Objective: To study the curative efficacy of milrinone combined with dopaminein treatment of chronic heart failure and effects on Cystatin C(CysC), N-terminal B type natriuretic peptide precursor(NT-proBNP), interleukin-6(IL-6) levels. Methods: 65 patients of chronic heart failure who received therapy from June 2017 to September 2018 in our hospital were selected as research objects, they were divided into observation group (35 cases) and control group (30 cases) by simple random number table method. The control group was given routine treatment, while the observation group was given milrinone combined with dopamine without digitalis preparation, they were continuous treatment for 7d. The clinical efficacy, the changes of serum CysC, NT-proBNP, IL-6 and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate in the observation group was significantly higher than those in the control group(P<0.05); there were significant differences in the interaction of left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), serum CysC, NT-proBNP and IL-6 between groups at interblock·different time points(P<0.05); there were no adverse reactions such as abnormal liver and kidney function, abnormal blood and urine routine, and 1 case of ventricular premature contraction in the observation group. Conclusion: Milrinone combined with dopaminein is well for chronic heart failure, which can effectively reduce the expression of serum CysC, NT-proBNP and IL-6, the clinical application value is high.
|
|
|
|
|
|
[1] 邱伯雍,王永霞.慢性心力衰竭流行病学及防治研究进展[J].中华实用诊断与治疗杂志,2017,31(6):619~621.
[2] 黄峻.中国心力衰竭流行病学特点和防治策略[J].中华心脏与心律电子杂志,2015,3(2):2~3.
[3] Nanayakkara S, Mak V, Crannitch K, et al. Extended release oral milrinone, CRD-102, for advanced heart failure[J]. Am Cardiol, 2018, 122(6): 1017~1020.
[4] Erken Pamukcu H, Gerede Uludag DM, Tekin Tak B, et al. Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography[J]. Anatol Cardiol, 2018, 20(4): 213~219.
[5] Davarzani N, Sanders-van Wijk S, Maeder MT, et al. Novel concept to guide systolic heart failure medication by repeated biomarker testing-results: from TIME-CHF in context of predictive, preventive, and personalized medicine[J].EPMA, 2018, 9(2): 161~173.
[6] 尹杰.血清胱抑素C水平对慢性心力衰竭患者近期预后的临床研究[J].检验医学与临床,2015,12(13):1848~1849.
[7] Lomis N, Gaudreault F, Malhotra M, et al. Novel milrinone nanoformulation for use in cardiovascular diseases: preparation and in vitro characterization[J]. Mol Pharm, 2018, 15(7): 2489~2502.
[8] 赵世明.硝普钠联合多巴胺治疗慢性心衰的临床疗效观察[J].中国现代医生,2015,53(1):22~24. |
|
|
|
2019, Vol. 25 
